Drug recall: Kramer Novis Tusicof caplet CGMP deviations
ULTRAtab Laboratories is recalling Kramer Novis Tusicof caplets due to current Good Manufacturing Practice (CGMP) deviations. The recall affects approximately 639,729 tablets distributed to three wholesalers.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, but the source text does not report any illnesses, hospitalizations, or injuries. CGMP deviations are manufacturing quality failures and not inherently linked to patient harm in the source text. Per the rubric, Class II recalls without reported illness are scored as Moderate (2).
Plain-English summary
ULTRAtab Laboratories, Inc., headquartered in Highland, New York, is recalling Kramer Novis Tusicof caplets in bulk containers. Each caplet contains Guaifenesin 400 mg, Dextromethorphan HBr 20 mg, and Phenylephrine HCl 10 mg (NDC 62959-124-00). The recall was initiated on January 26, 2022, and covers approximately 639,729 tablets.
The recall was issued because the bulk product did not comply with current Good Manufacturing Practice (CGMP) requirements. The affected product codes are C119L, with bulk lots 18K028. ULTRAtab distributed the bulk product to three distributors, who may have subsequently distributed finished products to retailers or other entities.
This is a voluntary recall initiated by the firm through a letter to the FDA. The FDA classified this as a Class II recall. Consumers who have obtained this product should not use it and should return it to the place of purchase. Healthcare providers should notify their patients if they have distributed this product.
The recalled product
- Product
- Kramer Novis Tusicof Caplet (Guaifenesin 400 mg, Dextromethorphan HBr 20 mg, Phenylephrine HCl 10 mg) Bulk Container, ULTRAtab Laboratories, Inc., Highland, NY NDC 62959-124-00
- Manufacturer
- ULTRAtab Laboratories, Inc.
- Category
- Drug — Cough and Cold
- Affected units
- 639,729
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Product Codes: C119L Bulk Lots: 18K028
Distribution
Distribution scope not specified by the agency.
Part of a larger recall action
This product is one of 33 recalled by ULTRAtab Laboratories, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 33 products in this recall →Related recalls
Same manufacturer · ULTRAtab Laboratories, Inc.
See all →- ModerateDBI Magnums Caffeine Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2022-02-16
- ModerateHPC Tablet Drug Recalled Due to CGMP Manufacturing Deviations
FDA (Drugs) · 2022-02-16
- ModerateMelatonin ER supplement recalled for manufacturing practice deviations
FDA (Food) · 2022-02-16
- ModerateDietary supplement melatonin recall due to manufacturing deviations
FDA (Food) · 2022-02-16
- Moderate
Same hazard · cgmp violation
See all →- Moderatevite20 Antifungal Cream recalled due to stability testing deviations
FDA (Drugs) · 2026-07-08
- ModerateNeuroquell products recalled over current good manufacturing practice violations
FDA (Drugs) · 2025-09-17
- ModerateOptim V Anti-Itch Cream Recalled for Current Good Manufacturing Practice Deviations
FDA (Drugs) · 2025-05-28
- ModerateNature Mint Anticavity Fluoride Toothpaste Recalled for CGMP Deviations
FDA (Drugs) · 2025-05-28
- ModerateRapidol Hydrocortisone 1% Anti-Itch Cream Recalled for CGMP Deviations
FDA (Drugs) · 2025-05-28